Using an integrated functional genomics and machine learning drug discovery engine, the company synthesizes a wide range of mutations across validated oncological targets and in-licenses clinical stage small molecule assets to develop for hyper-targeted populations.
As part of the strategic refocus, the company has appointed therapeutic and business development veterans Dieter Weinand and Usama Malik as the chairman of the board, and chief executive officer and a director, respectively.
The previous chief executive officer of the company, Dr. Michael Vidne, will continue to work with the company and has transitioned to chief business and strategy officer.
The company is in the process of establishing its headquarters and executive leadership team in the US The company also anticipates it will complete its Phase 1 dose-finding study in the coming months, which the company hopes to follow with a launch of a pivotal Phase 2 study of its clinical Class I/II BRAF inhibitor, PLX8394.
Dieter Weinand brings decades of general management and commercial leadership experience with executive management roles at Bayer, Sanofi, Pfizer, and BMS among others. He also sits on the boards of several high-profile biotech companies, including as chairman of the board of directors of Replimune.
Usama Malik also brings extensive experience from across the healthcare industry into his new role. He has led, grown and transformed pharma and biotech organizations in executive leadership roles, and has been an advisor to the boards and leadership teams of numerous Fortune 100 companies.
He most recently led the turnaround of Immunomedics, which was acquired by Gilead Sciences for USD 21bn.
NovellusDX is a clinical-stage biotechnology company focused on hyper-targeting clinical-stage precision oncology therapies to patients with unaddressed tumor mutations.
Lead asset PLX8394 is a Class I/II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2 clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer driving genes, the NovellusDX R and D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer